Swedish Orphan Biovitrum announces that the company has made all payments and transfers of value to healthcare professionals and organisations from 2016 publicly available*, including sponsorships to attend meetings, grants and donations, speaker fees, consultancy and advisory boards in accordance with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code.
The information is made available on Sobi´s corporate web site, starting 31 May 2017.
Increased transparency provides a strong basis for continued collaboration and can positively impact the quality of research, development and manufacturing across the industry, hopes the company.
“Transparency is an integral part of driving a sustainable business and our quality work supporting the high integrity standards that patients, prescribers, budget holders and other stakeholders expect. The EFPIA disclosure code is an important initiative to build trust for and within our industry,” said Lars Dreiøe, SVP, Chief Quality and Compliance Officer at Sobi. “Dialogue and interaction between healthcare professionals and organisations is vital when it comes to building sustainable value to rare disease patients and rare disease communities around the world.”
EFPIA Disclosure Code
The EFPIA (European Federation of Pharmaceutical Industries and Associations) Disclosure Code is a formal code of conduct that requires all EFPIA member companies and companies which are members of EFPIA member associations to disclose transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs). The information is published on a public platform, which could be on the company’s own website or a central platform combing data from different companies.
*Date for final publication in all EU countries is 30 June 2017. The data will be continuously updated to this date.
Photo of Lars Dreiøe